Search review questions

Virologically confirmed dengue case incidence (any severity, any phenotype) · children and adults at risk of dengue infection

Prevalence of dengue RNA in the mosquito population · children and adults at risk of dengue infection

Mosquito density (for population suppression strategy) · children and adults at risk of dengue infection

Prevalence of Wolbachia‐carrying mosquitoes (for population replacement strategy) · children and adults at risk of dengue infection

Adverse events potentially related to Wolbachia‐carrying Aedes deployments · children and adults at risk of dengue infection

Cluster‐RCTs · adults and children

Cluster‐RCTs · adults and children

NRCTs · adults and children

Cluster‐RCTs · adults and children

Non‐randomized studies** · adults and children

Non‐randomized studies** · adults and children

Cluster‐RCTs · adults and children

Non‐randomized studies** · adults and children

Viral clearance at 14 days · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression…

Participants with new need for invasive mechanical ventilation or death · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Participants discharged alive. Participants should be discharged without clinical deterioration or death · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Quality of life up to 28 days and longest · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

SAEs during the study period · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Any grade TEAE · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Any grade TRAE · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Discontinuation of study drug due to adverse events · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Viral clearance · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities

Admission to ICU or death · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression…

All initial symptoms resolved at 28 days, and up to the longest · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression…

Time to symptom resolution · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression…

Quality of life up to 28 days and longest · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression…

Outcomesa,b,c · adults and children with uncomplicated malaria

Outcomesa · adults and children with uncomplicated P falciparum malaria

Duration of hospital stay · children under 18 years of age with enteric fever

Convalescent faecal carriage · children under 18 years of age with enteric fever

Serious adverse events · children under 18 years of age with enteric fever

Serious adverse events · adults and children with enteric fever

Duration of hospital stay · adults and children with enteric fever

Convalescent faecal carriage · adults and children with enteric fever

Serious adverse events · adults and children with enteric fever

Outcome (design) · children and adults

Strongyloides stercoralis prevalence · children and adults

Specimen · children with presumed pulmonary tuberculosis Index tests: Xpert Ultra Role: an initial test Threshold for index…

Specimen · children with presumed pulmonary tuberculosis Index tests: Xpert Ultra Role: an initial test Threshold for index…

Test result · people with presumptive pulmonary tuberculosisRole: an initial testIndex test: Xpert MTB/XDRThreshold for index test:…

Test result · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin…

Test result · adults with pulmonary tuberculosis with known rifampicin resistance, detected as tuberculosis positive by Xpert…

Test result · adults with pulmonary tuberculosis with known rifampicin resistance, detected as tuberculosis‐positive by Xpert…

Test result · adults with pulmonary tuberculosis irrespective of rifampicin resistance (i.e. whether or not their rifampicin…

Improvement of clinical status: time to symptom resolution · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§

QoL at longest · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings…

Severe all‐cause diarrhoea · children

Severe all‐cause diarrhoea · children

Severe cases of rotavirus diarrhoea · children

Severe all‐cause diarrhoea · children